Estimated IPD to CAP incidence rate ratio over the period 2008/09 to 2012/2013.

<p>Estimated IPD to CAP incidence rate ratio over the period 2008/09 to 2012/2013.</p

Observed and projected incidence for community acquired pneumonia caused by PCV7 vaccine types per 100.000 for the epidemiological years 2008/09 until 2019/20 in three age groups 65–74 (black line), 75–84 (light grey line) and 85 and over (dark grey line).

<p>Model projections, see text, are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.</p

Observed and projected incidence for invasive pneumococcal disease caused by the PCV13 minus PCV7 vaccine types per 100.000 persons for the epidemiological years 2002/03 until 2019/20 in three age groups 65–74 (black line), 75–84 (light grey line) and 85 and over (dark grey line).

<p>Future projections, see text, are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.</p

Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICER) and maximum price per dose; base case and sensitivity analysis.

<p>Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICER) and maximum price per dose; base case and sensitivity analysis.</p

Observed and projected incidence for invasive pneumococcal disease caused by the PCV7 vaccine types per 100.000 persons for the epidemiological years 2002/03 until 2019/20 in three age groups 65–74 (black), 75–84 (light grey) and 85 and over (dark grey line).

<p>Future projections, see text, are shown by a dotted line.</p

Projected future incidence of Invasive pneumococcal disease (IPD) and Community Acquired Pneumonia (CAP) caused by the PCV13 vaccine types per 100,000.

<p>In 2018/2019 a new steady state was assumed to be reached and the same incidence was continued after.</p

Observed and projected incidence for community acquired pneumonia caused by PCV13 minus PCV7 vaccine types per 100.000 for the epidemiological years 2008/09 until 2019/20 in three age groups 65–74 (dark line), 75–84 (light grey line) and 85 and over (dark grey line).

<p>Model projections, see text, are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.</p

Incidence of vaccine-type IPD and CAP as applied by year in the model, and the cost-effectiveness and maximum price per dose (threshold of £20,000) for the corresponding incidence in case this would be the long-term incidence.

<p>Incidence of vaccine-type IPD and CAP as applied by year in the model, and the cost-effectiveness and maximum price per dose (threshold of £20,000) for the corresponding incidence in case this would be the long-term incidence.</p

Observed incidence rate ratios for PCV7 vaccine types and PCV13 minus PCV7 serotypes in the three years after vaccination compared to the four years before vaccination (2002/03 to 2005/06 for PCV7 and 2007/08 to 2010/2011 for PCV13 minus PCV7).

<p>The dark shaded bars represent PCV7 and the light shaded bars PCV13 minus PCV7 types.</p

Serotype-specific differences in mortality between serotypes.

<p>The line shows the absolute case fatality rate for serotype 14, which was used as reference in the logistic regression. The p-values of this regression are shown above each bar. The whiskers show the 95% confidence intervals based on a binomial distribution. When there are no serotypes with ≥50 cases an empty plot is shown. a) Under 5 years; b) 5–64 years; c) 65+ years.</p